Nicole Fraser-Hurt

Nicole Fraser-Hurt

Auto-generated profile, based on publicly available information

Nicole Fraser-Hurt

World Bank, Washington, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in International Journal of Drug Policy
Verified
Journal Article
Open access
DWDavid P. Wilson
David P. Wilson
BDBraedon Donald
Braedon Donald
ASAndrew J. Shattock
Andrew J. Shattock
DWDavid Wilson
David Wilson
NFNicole Fraser-Hurt
Nicole Fraser-Hurt
HIV prevalence worldwide among people who inject drugs (PWID) is around 19%. Harm reduction for PWID includes needle-syringe programs (NSPs) and opioid substitution therapy (OST) but often coupled with antiretroviral therapy (ART) for people living with HIV. Numerous studies have examined the effectiveness of each harm reduction strategy. This commentary discusses the evidence of effectiveness of the packages of harm reduction services and their cost-effectiveness with respect to HIV-related outcomes as well as estimate resources required to meet global and regional coverage targets. NSPs have been shown to be safe and very effective in reducing HIV transmission in diverse settings; there are many historical and very recent examples in diverse settings where the absence of, or reduction in, NSPs have resulted in exploding HIV epidemics compared to controlled epidemics with NSP implementation. NSPs are relatively inexpensive to implement and highly cost-effective according to commonly used willingness-to-pay thresholds. There is strong evidence that substitution therapy is effective, reducing the risk of HIV acquisition by 54% on average among PWID. OST is relatively expensive to implement when only HIV outcomes are considered; other societal benefits substantially improve the cost-effectiveness ratios to be highly favourable. Many studies have shown that ART is cost-effective for keeping people alive but there is only weak supportive, but growing evidence, of the additional effectiveness and cost-effectiveness of ART as prevention among PWID. Packages of combined harm reduction approaches are highly likely to be more effective and cost-effective than partial approaches. The coverage of harm reduction programs remains extremely low across the world. The total annual costs of scaling up each of the harm reduction strategies from current coverage levels, by region, to meet WHO guideline coverage targets are high with ART greatest, followed by OST and then NSPs. But scale-up of all three approaches is essential. These interventions can be cost-effective by most thresholds in the short-term and cost-saving in the long-term.

23 July 2019 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MFMatthew P. Fox
Matthew P. Fox
SPSophie Pascoe
Sophie Pascoe
AHAmy N. Huber
Amy N. Huber
JMJoshua Murphy
Joshua Murphy
MPMokgadi Phokojoe
Mokgadi Phokojoe
NFNicole Fraser-Hurt
Nicole Fraser-Hurt
Differentiated antiretroviral therapy (ART) delivery models, in which patients are provided with care relevant to their current status (e.g., newly initiating, stable on treatment, or unstable on treatment) has become an essential part of patient-centered health systems. In 2015, the South African government implemented Chronic Disease Adherence Guidelines (AGLs), which involved five interventions: Fast Track Initiation Counseling for newly initiating patients, Enhanced Adherence Counseling for patients with an unsuppressed viral load, Early Tracing of patients who miss visits, and Adherence Clubs (ACs) and Decentralized Medication Delivery (DMD) for stable patients. We evaluated two of these interventions in 24 South African facilities: ACs, in which patients meet in groups outside usual clinic procedures and receive medication; and DMD, in which patients pick up their medication outside usual pharmacy queues. We compared those participating in ACs or receiving DMD at intervention sites to those eligible for ACs or DMD at control sites. Outcomes were retention and sustained viral suppression (<400 copies/mL) 12 months after AC or DMD enrollment (or comparable time for controls). 12 facilities were randomly allocated to intervention and 12 to control arms in four provinces (Gauteng, North West, Limpopo, and KwaZulu Natal). We calculated adjusted risk differences (aRDs) with cluster adjustment using generalized estimating equations (GEEs) using difference in differences (DiD) with patients eligible for ACs/DMD prior to implementation (Jan 1, 2015) for comparison. For DMD, randomization was not preserved, and the analysis was treated as observational. For ACs, 275 intervention and 294 control patients were enrolled; 72% of patients were female, 61% were aged 30–49 years, and median CD4 count at ART initiation was 268 cells/μL. AC patients had higher 1-year retention (89.5% versus 81.6%, aRD: 8.3%; 95% CI: 1.1% to 15.6%) and comparable sustained 1-year viral suppression (<400 copies/mL any time ≤ 18 months) (80.0% versus 79.6%, aRD: 3.8%; 95% CI: −6.9% to 14.4%). Retention associations were apparently stronger for men than women (men RD: 13.1%, 95% CI: 0.3% to 23.5%; women RD: 6.0%, 95% CI: −0.9% to 12.9%). For DMD, 232 intervention and 346 control patients were enrolled; 71% of patients were female, 65% were aged 30–49 years, and median CD4 count at ART initiation was 270 cells/μL. DMD patients had apparently lower retention (81.5% versus 87.2%, aRD: −5.9%; 95% CI: −12.5% to 0.8%) and comparable viral suppression versus standard of care (77.2% versus 74.3%, aRD: −1.0%; 95% CI: −12.2% to 10.1%), though in both cases, our findings were imprecise. We also noted apparently increased viral suppression among men (RD: 11.1%; 95% CI: −3.4% to 25.5%). The main study limitations were missing data and lack of randomization in the DMD analysis. In this study, we found comparable DMD outcomes versus standard of care at facilities, a benefit for retention of patients in care with ACs, and apparent benefits in terms of retention (for AC patients) and sustained viral suppression (for DMD patients) among men. This suggests the importance of alternative service delivery models for men and of community-based strategies to decongest primary healthcare facilities. Because these strategies also reduce patient inconvenience and decongest clinics, comparable outcomes are a potential success. The cost of all five AGL interventions and possible effects on reducing clinic congestion should be investigated. NCT02536768.

17 July 2018 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
WVWillem Venter
Willem Venter
JCJesse Coleman
Jesse Coleman
VCVincent Lau Chan
Vincent Lau Chan
ZSZara Shubber
Zara Shubber
MPMothepane Phatsoane
Mothepane Phatsoane
NFNicole Fraser-Hurt
Nicole Fraser-Hurt
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

2 April 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
WVWillem Daniel Francois Venter
Willem Daniel Francois Venter
AFAlex Fischer
Alex Fischer
SLSamanta Lalla-Edward
Samanta Lalla-Edward
JCJesse Coleman
Jesse Coleman
VCVincent Lau Chan
Vincent Lau Chan
NFNicole Fraser-Hurt
Nicole Fraser-Hurt
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

31 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TKTendesayi Kufa
Tendesayi Kufa
ZSZara Shubber
Zara Shubber
WMWilliam MacLeod
William MacLeod
STSimbarashe Takuva
Simbarashe Takuva
SCSergio Carmona
Sergio Carmona
NFNicole Fraser-Hurt
Nicole Fraser-Hurt
We describe CD4 count recovery among HIV positive individuals who initiated antiretroviral therapy (ART) with and without severe immune suppression using complete laboratory data from South Africa’s national HIV treatment programme between 2010 and 2014 and discuss implications for CD4 count monitoring. Retrospective analysis of routinely collected laboratory data from South Africa’s National Health Laboratory Service (NHLS). A probabilistic record linkage algorithm was used to create a cohort of HIV positive individuals who initiated ART between 2010 and 2014 based on timing of CD4 count and viral load measurements. A CD4 count < 50 copies/μl at ART initiation was considered severe immunosuppression. A multivariable piecewise mixed-effects linear regression model adjusting for age, gender, year of starting ART, viral suppression in follow up and province was used to predict CD4 counts during follow up. 1,070,900 individuals had evidence of starting ART during 2010–2014 and met the criteria for inclusion in the cohort -46.6% starting ART with CD4 < 200 cells/μl and 10.1% with CD4 < 50 cells/ μl. For individuals with CD4 counts < 200 cells/μl, predicted CD4 counts > 200 cells/μl, >350 cells/μl and >500 cells/μl corresponded with mean follow up durations of 1.5 years (standard deviation [s.d] 1.1), 1.9years (s.d 1.2) and 2.1 years (s.d 1.3 years). For those with CD4 counts < 50 cells/μl, predicted CD4 count above these threshold corresponded with mean follow up durations of 2.5 years (s.d 0.9 years), 4.4 years (s.d 0.4 years) and 5.0 years (s.d 0.1years) for recovery to the same thresholds. CD4 count recovery varied mostly with duration on ART, CD4 count at the start of ART and gender. For individuals starting with ART with severe immunosuppression, CD4 recovery to 200cells/μl did not occur or took longer than 12 month for significant proportions. CD4 monitoring and interventions recommended for advanced HIV disease should continue until full recovery.

13 April 2018 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
RSRobyn M Stuart
Robyn M Stuart
LGLaura Grobicki
Laura Grobicki
HHHassan Haghparast-Bidgoli
Hassan Haghparast-Bidgoli
JPJasmina Panovska‐Griffiths
Jasmina Panovska‐Griffiths
JSJolene Skordis
Jolene Skordis
DWDavid P Wilson
David P Wilson
Introduction: With limited funds available, meeting global health targets requires countries to both mobilize and prioritize their health spending. Within this context, countries have recognized the importance of allocating funds forHIVas efficiently as possible to maximize impact. Over the past six years, the governments of 23 countries in Africa, Asia, Eastern Europe and Latin America have used the OptimaHIVtool to estimate the optimal allocation ofHIVresources.Methods: Each study commenced with a request by the national government for technical assistance in conducting anHIVallocative efficiency study using OptimaHIV. Each study team validated the required data, calibrated the OptimaHIVepidemic model to produceHIVepidemic projections, agreed on cost functions for interventions, and used the model to calculate the optimal allocation of available funds to best address national strategic plan targets. From a review and analysis of these 23 country studies, we extract common themes around the optimal allocation ofHIVfunding in different epidemiological contexts.Results and discussion: The optimal distribution ofHIVresources depends on the amount of funding available and the characteristics of each country's epidemic, response and targets. Universally, the modelling results indicated that scaling up treatment coverage is an efficient use of resources. There is scope for efficiency gains by targeting theHIVresponse towards the populations and geographical regions whereHIVincidence is highest. Across a range of countries, the model results indicate that a more efficient allocation ofHIVresources could reduce cumulative newHIVinfections by an average of 18% over the years to 2020 and 25% over the years to 2030, along with an approximately 25% reduction in deaths for both timelines. However, in most countries this would still not be sufficient to meet the targets of the national strategic plan, with modelling results indicating that budget increases of up to 185% would be required.Conclusions: Greater epidemiological impact would be possible through better targeting of existing resources, but additional resources would still be required to meet targets. Allocative efficiency models have proven valuable in improving theHIVplanning and budgeting process.